Bakris George L, Tarka Elizabeth A, Waterhouse Brian, Goulding Michelle R, Madan Anuradha, Anderson Karen M, St John Sutton Martin, Miller Alan B, Reichek Nathaniel
Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA.
Am J Cardiol. 2006 Oct 2;98(7A):46L-52L. doi: 10.1016/j.amjcard.2006.08.002. Epub 2006 Aug 28.
Patients at high risk for hypertension may require several therapeutic agents to lower their blood pressure to guideline-recommended targets. Some antihypertensive agents are more effective than others in protecting against cardiovascular morbidity and mortality. Numerous beta-blocking agents have been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. Previous trials have demonstrated that although all beta-blockers effectively reduce blood pressure, there are differences in how they affect various metabolic factors. In 2 trials, a novel controlled-release (CR) formulation of carvedilol will be tested against other selective beta-blockers to determine whether differences exist in their individual effects on cardiovascular risk factors. These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors.
高血压高危患者可能需要几种治疗药物才能将血压降至指南推荐的目标值。在预防心血管疾病发病率和死亡率方面，一些抗高血压药物比其他药物更有效。许多β受体阻滞剂已获得美国食品药品监督管理局（FDA）批准用于治疗高血压。先前的试验表明，虽然所有β受体阻滞剂都能有效降低血压，但它们对各种代谢因素的影响存在差异。在两项试验中，将对一种新型的卡维地洛控释（CR）制剂与其他选择性β受体阻滞剂进行测试，以确定它们对心血管危险因素的个体影响是否存在差异。这将是首批使用卡维地洛CR进行的直接对比试验，以确定β受体阻滞剂之间不同的药理作用是否会对心血管危险因素产生不同的影响。
